Asciminib - Novartis

Drug Profile

Asciminib - Novartis

Alternative Names: ABL 001; Asciminib hydrochloride

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Pyrazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic myeloid leukaemia
  • Phase I Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 30 Jul 2018 Novartis plans a phase I pharmacokinetic trial for Impaired renal function (In volunteers) (PO) (NCT03605277)
  • 27 Jul 2018 Dana-Farber Cancer Institute and Novartis plan a phase I trial for Chronic myeloid leukaemia and Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy) in USA in July 2018 (NCT03595917)
  • 12 Jul 2018 Phase-I development in Acute-lymphoblastic-leukaemia (Second-line therapy or greater) in Spain, Singapore, Italy, France, USA, Netherlands, South Korea, Japan, Germany, Australia (PO) and Chronic-myeloid-leukaemia (Second-line therapy or greater) in Singapore is ongoing (NCT02081378)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top